Harmony Biosciences Holdings Inc (HRMY)
34.07
+0.84
(+2.53%)
USD |
NASDAQ |
Nov 22, 16:00
34.07
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Enterprise Value: 1.715B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 1.715B |
| November 21, 2024 | 1.668B |
| November 20, 2024 | 1.642B |
| November 19, 2024 | 1.625B |
| November 18, 2024 | 1.658B |
| November 15, 2024 | 1.667B |
| November 14, 2024 | 1.654B |
| November 13, 2024 | 1.702B |
| November 12, 2024 | 1.773B |
| November 11, 2024 | 1.820B |
| November 08, 2024 | 1.830B |
| November 07, 2024 | 1.763B |
| November 06, 2024 | 1.728B |
| November 05, 2024 | 1.678B |
| November 04, 2024 | 1.657B |
| November 01, 2024 | 1.659B |
| October 31, 2024 | 1.605B |
| October 30, 2024 | 1.700B |
| October 29, 2024 | 2.139B |
| October 28, 2024 | 1.811B |
| October 25, 2024 | 1.740B |
| October 24, 2024 | 1.714B |
| October 23, 2024 | 1.714B |
| October 22, 2024 | 1.760B |
| October 21, 2024 | 1.766B |
| Date | Value |
|---|---|
| October 18, 2024 | 1.792B |
| October 17, 2024 | 1.767B |
| October 16, 2024 | 1.759B |
| October 15, 2024 | 1.797B |
| October 14, 2024 | 1.796B |
| October 11, 2024 | 1.759B |
| October 10, 2024 | 1.758B |
| October 09, 2024 | 1.689B |
| October 08, 2024 | 1.754B |
| October 07, 2024 | 1.733B |
| October 04, 2024 | 1.746B |
| October 03, 2024 | 1.755B |
| October 02, 2024 | 1.801B |
| October 01, 2024 | 2.010B |
| September 30, 2024 | 2.054B |
| September 27, 2024 | 2.063B |
| September 26, 2024 | 2.101B |
| September 25, 2024 | 1.959B |
| September 24, 2024 | 1.989B |
| September 23, 2024 | 2.013B |
| September 20, 2024 | 2.073B |
| September 19, 2024 | 2.055B |
| September 18, 2024 | 2.019B |
| September 17, 2024 | 2.045B |
| September 16, 2024 | 2.042B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
951.04M
Minimum
Oct 27 2023
3.497B
Maximum
Dec 05 2022
2.122B
Average
2.008B
Median
Jun 23 2023
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 73.29B |
| Incyte Corp | 12.04B |
| EyePoint Pharmaceuticals Inc | 357.05M |
| Cassava Sciences Inc | 1.125B |
| Capricor Therapeutics Inc | 761.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 46.09M |
| Revenue (Quarterly) | 186.04M |
| Total Expenses (Quarterly) | 124.33M |
| EPS Diluted (Quarterly) | 0.79 |
| Gross Profit Margin (Quarterly) | 77.01% |
| Profit Margin (Quarterly) | 24.78% |
| Earnings Yield | 6.19% |
| Operating Earnings Yield | 8.87% |
| Normalized Earnings Yield | 6.193 |